British American Tobacco (BAT; LSE: BATS) has announced the launch of KBio Holdings (KBio), a biotech company focused on accelerating the research, development and production of new treatments for rare and infectious diseases.
KBio will leverage the existing and extensive plant-based technology capabilities of BAT and Kentucky BioProcessing (KBP), the existing BAT-owned US plant biologics organization.
The company will explore new opportunities to develop its plant-based production system, which has the potential to offer greater speed, scale-up opportunity and thermostability.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze